Media coverage about Impax Laboratories (NASDAQ:IPXL) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Impax Laboratories earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 46.503140015714 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Amneal Gains Approval for Erythromycin Tablets USP (finance.yahoo.com)
- $0.17 Earnings Per Share Expected for Impax Laboratories Inc (IPXL) This Quarter (americanbankingnews.com)
- Impax faces U.S. antitrust trial over generic acne drug’s delay (finance.yahoo.com)
- Impax broke U.S. antitrust law by delaying generic drug, jury told (finance.yahoo.com)
- Brokers Issue Forecasts for Impax Laboratories Inc’s Q1 2018 Earnings (IPXL) (americanbankingnews.com)
Impax Laboratories (NASDAQ:IPXL) traded down $0.30 during trading on Wednesday, hitting $20.45. The stock had a trading volume of 256,374 shares, compared to its average volume of 989,743. The stock has a market capitalization of $1,489.82, a PE ratio of -3.15, a PEG ratio of 0.86 and a beta of 1.01. The company has a debt-to-equity ratio of 4.11, a current ratio of 1.96 and a quick ratio of 1.52. Impax Laboratories has a 1-year low of $8.80 and a 1-year high of $25.70.
A number of brokerages have weighed in on IPXL. BidaskClub raised Impax Laboratories from a “sell” rating to a “hold” rating in a research report on Wednesday. Canaccord Genuity set a $19.00 price objective on Impax Laboratories and gave the company a “hold” rating in a research note on Thursday, March 1st. Guggenheim initiated coverage on Impax Laboratories in a research note on Tuesday, December 12th. They issued a “neutral” rating and a $18.00 price target for the company. Cowen set a $21.00 price target on Impax Laboratories and gave the stock a “hold” rating in a research note on Thursday, March 1st. Finally, Cantor Fitzgerald set a $35.00 target price on Impax Laboratories and gave the company a “buy” rating in a research report on Thursday, March 1st. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company’s stock. Impax Laboratories currently has an average rating of “Hold” and a consensus target price of $20.91.
Impax Laboratories Company Profile
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.